Global Maternal Mental Health Market Size Study & Forecast, by Disease Indication (Postpartum Depression, Dysthymia, Pregnancy and Postpartum General Anxiety, Pregnancy and Postpartum OCD, Birth-Related PTSD, Others), by Therapy (Antidepressants, Interper

Global Maternal Mental Health Market Size Study & Forecast, by Disease Indication (Postpartum Depression, Dysthymia, Pregnancy and Postpartum General Anxiety, Pregnancy and Postpartum OCD, Birth-Related PTSD, Others), by Therapy (Antidepressants, Interpersonal Psychotherapy (IPT), Cognitive Behavioral Therapy (CBT), Others), and Regional Analysis, 2023-2030

Global Maternal Mental Health Market is valued at approximately USD 6.22 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 28.43% over the forecast period 2023-2030. Maternal mental health is a type of psychological well-being among women during pregnancy and the postpartum period or perinatal period. It encompasses a wide range of mental health conditions and challenges that some women experience during and after pregnancy. The Maternal Mental Health Market is expanding because of factors such as increased government investment in attempts to lower maternal mortality, rising rates of postpartum depression, increased awareness campaigns, and improvements in practices relating to maternal mental health. Globally, maternal mental health is a significant issue since it influences not only mothers' well-being but also the health and development of their offspring. According to recent research by PostpartumDepression.org, one in seven women is likely to have postpartum depression in 2023. There are around 600,000 cases of postpartum depression among the four million live births that occur in the United States each year.

In addition, the increasing financing for research, instruction, and treatment around maternal mental health is an important concern and is acting as a catalyzing factor for the market growth during the estimated period. For instance, in December 2022, The United Chinese Community Enrichment Services Society, commonly known as S.U.C.C.E.S.S., received a USD 1.2 million grant from the Government of Canada to promote postpartum mothers' and their families' mental health in Asian and South Asian immigrant communities. The funding assists S.U.C.C.E.S.S. to enhance the referral processes used by physicians and midwives to connect various immigrant groups in the Tri-Cities area of British Columbia with social services including mental health care. Thus, these aforementioned factors are propelling the growth of the Maternal Mental Health Market during the estimated period. Moreover, the increasing advancements in personalized medicine and precision healthcare, as well as the rise of digital health solutions, telemedicine, and mental health apps present various lucrative opportunities over the forecast years. However, the inadequate availability of mental health services in underdeveloped and developing countries and the lack of trained professionals are challenging the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Maternal Mental Health Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the favorable reimbursement scenarios, rising PPD prevalence, growing awareness campaigns, and a strong healthcare infrastructure. Whereas, Asia Pacific is expected to grow at the highest CAGR over the forecast years. The growing awareness of maternal mental health issues, the high presence of the female population, coupled with the rising prevalence of maternal mental health disorders is significantly propelling the market demand across the region.

Major market players included in this report are:
Therapy Mama
Canopie
Pfizer Inc
Viatris Inc.
GlaxoSmithKline PLC
Alembic Pharmaceuticals Limited
Mallinckrodt Pharmaceuticals
Sage Therapeutics, Inc.
Bausch Health Companies Inc.
Magellan Health, Inc.

Recent Developments in the Market:
In February 2023, Biogen Inc. and Sage Therapeutics, Inc. unveiled that the U.S. FDA has accepted the filing of a New Drug Application for zuranolone in the treatment of PPD and major depressive disorder. The claim has facilitated the priority review and the FDA has consigned a Prescription Drug User Fee Act action date of August 5, 2023.

Global Maternal Mental Health Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Disease Indication, Therapy, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Disease Indication:
Postpartum Depression
Dysthymia
Pregnancy and Postpartum General Anxiety
Pregnancy and Postpartum OCD
Birth-Related PTSD
Others

By Therapy:
Antidepressants
Interpersonal Psychotherapy (IPT)
Cognitive Behavioral Therapy (CBT)
Others

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Therapy Mama
Canopie
Pfizer Inc
Viatris Inc.
GlaxoSmithKline PLC
Alembic Pharmaceuticals Limited
Mallinckrodt Pharmaceuticals
Sage Therapeutics, Inc.
Bausch Health Companies Inc.
Magellan Health, Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.